Maximilian Diehn, M.D., Ph.D.
Publication Details
-
Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.
Int J Radiat Oncol Biol Phys. 2010; (2): 323-7
To evaluate the effect of tumor hypoxia on the expected level of cell killing by regimens of stereotactic ablative radiotherapy (SABR) and to determine the extent to which the negative effect of hypoxia could be prevented using a clinically available hypoxic cell radiosensitizer.
Help
Trial Administration